The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and ...

Imfinzi is a human monoclonal antibody that targets the PD-L1 protein, whereas Imjudo focuses on the CTLA-4 protein.

The company has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution ...

AstraZeneca Plc’s Imfinzi extended the lives of patients with bladder cancer, potentially opening up a new market for the ...

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with ...

Reliance Power, Vodafone Idea, SpiceJet, NHPC, PNB - Stocks to Watch: Tuesday,4, 2024 Markets in India are poised for a ...

The NIAGARA trial with Imfinzi is the first study to show an OS benefit in both the neoadjuvant and adjuvant settings.